Results 21 to 30 of about 147,286 (225)
Key Clinical Message Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many features in common and may coincide in the same patient. Timely diagnosis and management of visceral leishmaniasis could save patients from unnecessary toxic ...
Anwar I. Joudeh +6 more
doaj +1 more source
Synthesis, Antiparasitic Activity, and ADME Profile of Morpholinephenylbenzamides: A Pharmacological Study Against Chagas Disease and Visceral Leishmaniasis [PDF]
Hit‐to‐lead optimization of morpholinephenylbenzamides reveals key structure–activity relationships against Trypanosoma cruzi and Leishmania infantum. Potency, selectivity, and ADME properties are differentially improved across the series, identifying compounds 20, 24, and 16 as complementary templates for the future design of dual antiparasitic leads.
Farago D +15 more
europepmc +2 more sources
Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review
Visceral leishmaniasis, also known as kala-azar is one of the most commonly neglected tropical diseases affecting a large number of rural and resource-limited people in South Asia, Africa, and South America.
Pashupati Pokharel +2 more
doaj +1 more source
Immunobiology of visceral leishmaniasis [PDF]
Visceral leishmaniasis (VL), commonly known as kala-azar, is caused by Leishmania donovani and Leishmania infantum (Leishmania chagasi in the Americas). These Leishmania species infect macrophages throughout the viscera, and parasites are typically found in the spleen, liver, and bone marrow.
Kumar, Rajiv, Nylén, Susanne
openaire +3 more sources
Visceral leishmaniasis (VL) is a neglected tropical disease (NTD) caused by Leishmania protozoa that are transmitted by female sand flies. On the Indian subcontinent (ISC), VL is targeted by the World Health Organization (WHO) for elimination as a public
NTD Modelling Consortium Visceral Leishmaniasis Group
doaj +1 more source
Diagnosis of visceral leishmaniasis [PDF]
Leishmaniasis is a vector-borne disease with up to 350 million people at risk of infection worldwide. Among its different clinical manifestations, visceral is the most severe form. Since clinical features of visceral leishmaniasis (VL) mimic several other common diseases, accurate diagnosis is crucial as the treatment is associated with significant ...
Pankaj, Srivastava +3 more
openaire +2 more sources
Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial [PDF]
Alternative treatments for visceral leishmaniasis (VL) are required in East Africa.
Makonnen, Eyasu +151 more
core +1 more source
Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity
Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many different species within the genus Leishmania, is an unfamiliar disease to most North American providers.
John M. Curtin, Naomi E. Aronson
doaj +1 more source
Kidney involvement in leishmaniasis—a review
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania transmitted by insects of the genus Lutzomyia sp. or Phlebotomus sp.
Geraldo Bezerra da Silva Junior +2 more
doaj +1 more source
Visceral leishmaniasis in eastern Africa--current status. [PDF]
Visceral leishmaniasis (VL) is among the most neglected of the tropical diseases, afflicting the poorest of the poor. In eastern Africa, VL causes at least 4000 deaths annually, a loss of approximately 385,000 disability-adjusted life years.
Reithinger, Richard +2 more
core +1 more source

